The decline in revenue can be attributed to decreased sales of the Vitoss Synthetic Bone Graft Substitute products, which declined 6 percent in 4Q 2010 compared to 4Q 2009. Although sales of Vitoss Bioactive Foam products and Vitoss Morsels increased 3 percent and 1 percent, respectively, these increases were offset by a significant decrease in sales of Vitoss Foam products.
Read the company news release about Orthovita’s 4Q financial results (pdf).
Read other coverage about device companies’ financial results:
– MAKO Surgical Posts 4Q Revenue of $14.8M, 67% Increase
– Exactech Announces 4Q Revenue of $51.8M, 7% Increase
– TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
